Cognition Therapeutics (CGTX) Assets Average (2021 - 2026)
Cognition Therapeutics (CGTX) posted quarterly Assets Average of $42.3 million for Q1 2026, up 57.31% year-over-year from $26.9 million in Q1 2025, and down 7.9% quarter-over-quarter from $45.9 million in Q4 2025.
Cognition Therapeutics (CGTX) Assets Average (2021 - 2026) Analysis & Trends
Cognition Therapeutics (CGTX) has reported Assets Average for 6 consecutive years, with $42.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 57.31% year-over-year to $42.3 million; the TTM figure through Mar 2026 stood at $42.3 million (up 57.31% YoY), while the FY2025 annual figure was $39.3 million, up 20.23% from the prior year.
- Assets Average fell to $42.3 million in Q1 2026 per CGTX's latest filing, from $45.9 million in the prior quarter.
- Across five years, Assets Average topped out at $58.9 million in Q1 2022 and bottomed at $21.6 million in Q2 2025.
- Historically, Assets Average has averaged $40.7 million across 5 years, with a median of $41.4 million in 2023.
- On a YoY basis, Assets Average climbed as much as 58.76% in 2025 and fell as far as 41.11% in 2025.
- Cognition Therapeutics' Assets Average stood at $52.0 million in 2022, then slipped by 28.9% to $37.0 million in 2023, then fell by 21.81% to $28.9 million in 2024, then jumped by 58.76% to $45.9 million in 2025, then declined by 7.9% to $42.3 million in 2026.
- Business Quant data shows CGTX's Assets Average at $42.3 million in Q1 2026, $45.9 million in Q4 2025, and $31.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.23 Bn | 132.38 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.97 Bn | 78.97 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.88 Bn | 54.74 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.20 Bn | 37.11 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.69 Bn | 10.30 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - | 19.82 Bn |
| 10 | Cognition Therapeutics | 89.81 Mn | 89.81 Mn | - | 37.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.52 Mn |
| Mar 31, 2026 | 42.27 Mn |
| Dec 31, 2025 | 45.89 Mn |
| Sep 30, 2025 | 31.51 Mn |
| Jun 30, 2025 | 21.56 Mn |
| Mar 31, 2025 | 26.87 Mn |
| Dec 31, 2024 | 28.91 Mn |
| Sep 30, 2024 | 30.97 Mn |
| Jun 30, 2024 | 36.61 Mn |
| Mar 31, 2024 | 37.01 Mn |
| Dec 31, 2023 | 36.97 Mn |
| Sep 30, 2023 | 41.37 Mn |
| Jun 30, 2023 | 44.81 Mn |
| Mar 31, 2023 | 48.04 Mn |
| Dec 31, 2022 | 51.99 Mn |
| Sep 30, 2022 | 53.18 Mn |
| Jun 30, 2022 | 55.75 Mn |
| Mar 31, 2022 | 58.92 Mn |
| Dec 31, 2021 | 36.26 Mn |